@article{6de146f598a74ada9111d484e1db3904,
title = "IQ driving QI: the Asia Pacific Consortium on Osteoporosis (APCO): an innovative and collaborative initiative to improve osteoporosis care in the Asia Pacific",
abstract = "Summary: Asia Pacific Consortium on Osteoporosis (APCO) comprises of clinical experts from across the Asia Pacific region, uniting to develop solutions to problems facing osteoporosis management and care. The vision of APCO is to reduce the burden of osteoporosis and fragility fractures in the Asia Pacific region. Introduction: The Asia Pacific (AP) region comprises 71 countries with vastly different healthcare systems. It is predicted that by 2050, more than half the world{\textquoteright}s hip fractures will occur in this region. The Asia Pacific Consortium on Osteoporosis (APCO) was set up in May 2019 with the vision of reducing the burden of osteoporosis and fragility fractures in the AP region. Methods: APCO has so far brought together 39 clinical experts from countries and regions across the AP to develop solutions to challenges facing osteoporosis management and fracture prevention in this highly populous region of the world. APCO aims to achieve its vision by engaging with relevant stakeholders including healthcare providers, policy makers and the public. The initial APCO project is to develop and implement a Framework of pan-AP minimum clinical standards for the screening, diagnosis and management of osteoporosis. Results and conclusions: The Framework will serve as a platform upon which new national clinical guidelines can be developed or existing guidelines be revised, in a standardised fashion. The Framework will also facilitate benchmarking for provision of quality of care. It is hoped that the principles underlying the formation and functioning of APCO can be adopted by other regions and that every health care facility and progressively every country in the world can follow our aspirational path and progress towards best practice.",
keywords = "Asia Pacific, Clinical standards, Collaboration, Fragility fracture, Osteoporosis, Quality improvement",
author = "{on behalf of the Asia Pacific Consortium on Osteoporosis} and M. Chandran and Bhadada, {S. K.} and Ebeling, {P. R.} and Gilchrist, {N. L.} and Khan, {A. H.} and P. Halbout and S. Lekamwasam and G. Lyubomirsky and Mitchell, {P. J.} and Nguyen, {T. V.} and Tiu, {K. L.} and T. Amphansap and L. Asis and Bhadada, {S. K.} and Chan, {D. C.} and M. Chandran and M. Chadha and Chit, {T. T.} and Chung, {Y. S.} and H. Doshi and Gilchrist, {N. L.} and Hew, {F. L.} and {Habib Khan}, A. and P. Halbout and L. Ho-Pham and Latt, {T. S.} and E. Lau and Lau, {T. C.} and Lee, {D. O.} and Lee, {J. K.} and S. Lekamwasam and J. Liu and G. Lyubomirsky and A. Mithal and Mitchell, {P. J.} and Nguyen, {T. V.} and D. Pandey and I. Reid and Rhyu, {K. H.} and A. Suzuki and A. Taguchi and Thuy, {V. T.} and G. Tirtarahardja and Tiu, {K. L.} and C. Tolman and T. Vallenukal and W. Xia and Yung, {C. K.} and Y. Zhao",
note = "Funding Information: APCO gratefully acknowledges the contribution by Professor John Eisman AO (The Garvan Institute of Medical Research, Sydney, Australia) who laid the groundwork for initial discussions regarding the formation of the consortium. APCO also gratefully acknowledges Dr. Cae Tolman, Regional Medical Director, Bone Health, Amgen Asia and current pharmaceutical industry representative to the EXCO for his invaluable support in setting up APCO and promoting its cause. Editorial assistance was provided by Dr. Yoonah Choi of Evidencia Medical Communications Pty Ltd., contracted by APCO for the purpose. APCO Members: T. Amphansap, Police General Hospital, Bangkok, Thailand; L. Asis, University of the Philippines, Manila, Philippines; S. K. Bhadada, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India; D.C. Chan, National Taiwan University Hospital, Taiwan; M. Chandran, Osteoporosis and Bone Metabolism Unit, Singapore General Hospital, Singapore; M. Chadha, Hinduja Hospital and Research Centre, Mumbai, India; T.T. Chit, Yangon General Hospital, Yangon, Myanmar; Y. S. Chung, Ajou University School of Medicine, Suwon, Republic of Korea; H. Doshi, Gleneagles Medical Centre, Singapore, Singapore; P.R. Ebeling, Monash University, Melbourne, Australia; N. L. Gilchrist, Canterbury District Health Board, Christchurch, New Zealand; F.L. Hew, Puchong Medical Specialist Centre and Subang Jaya Medical Centre, Malaysia; A. Habib Khan, Aga Khan University, Karachi, Pakistan; P. Halbout, International Osteoporosis Foundation, Nyon, Switzerland; L. Ho-Pham, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam; T.S. Latt, Shwe Baho Hospital, Yangon, Myanmar; E. Lau, Hong Kong Orthopaedic and Osteoporosis Center for Treatment and Research, Hong Kong, Hong Kong SAR; T.C. Lau, National University Hospital, Singapore, Singapore; D.O. Lee, National Cancer Center, Goyang, Republic of Korea; J.K. Lee, Beacon Hospital, Petaling Jaya, Malaysia; S. Lekamwasam, University of Ruhuna, Matara, Sri Lanka; J. Liu, Shanghai Ruijin Hospital, Shanghai, China; G. Lyubomirsky, Osteoporosis Australia, Sydney, Australia; A. Mithal, Max Healthcare, Saket, New Delhi, India; P.J. Mitchell, Synthesis Medical NZ Limited, Auckland, New Zealand; T.V. Nguyen, The Garvan Institute of Medical Research, Sydney, Australia and University of Technology, Sydney, Australia; D. Pandey, National Trauma Centre, Kathmandu, Nepal; I. Reid, University of Auckland, Auckland, New Zealand; K. H. Rhyu, Kyung Hee University, Seoul, Republic of Korea; A. Suzuki, Fujita Health University, Toyoake, Japan; A. Taguchi, Matsumoto Dental University, Nagano, Japan; V. T. Thuy, Bach Mai Hospital, Hanoi, Vietnam; G. Tirtarahardja, Indonesian Osteoporosis Association (PEROSI), Jakarta, Indonesia; K.L. Tiu, Queen Elizabeth Hospital, Hong Kong, Hong Kong SAR; C. Tolman, Amgen Asia, Hong Kong, Hong Kong SAR; T. Vallenukal, Bhumibol Adulyadej Hospital, Bangkok, Thailand; W. Xia, Peking Union Medical College Hospital, Beijing, China; C.K. Yung, Raja Isteri Pengiran Anak Saleha Hospital, Bandar Seri Begawan, Brunei Darussalam; Y. Zhao, Beijing United Family Hospital, Beijing, China. Funding Information: Professor Peter Ebeling has research funding from Amgen, Eli-Lilly, Novartis and Alexion and has received honoraria from Amgen and Alexion. Funding Information: Amgen Asia provided financial support to fund secretariat function, event management and communication activities for the formation of APCO. Acknowledgements Funding Information: Professor Tuan Nguyen has received grant support from Amgen and honoraria for lectures and conference engagements from Novartis, MSD, Amgen and Bridge Health Care. Publisher Copyright: {\textcopyright} 2020, The Author(s).",
year = "2020",
month = nov,
day = "1",
doi = "10.1007/s00198-020-05495-w",
language = "English",
volume = "31",
pages = "2077--2081",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "11",
}